Skip to main content

Table 1 Estimated characteristic parameters of the tested antiviral drugs

From: Required concentration index quantifies effective drug combinations against hepatitis C virus infection

Drug

Type

Target

Class

IC50

m

RCI95

genotype 1b

genotype 2a

genotype 1b

genotype 2a

genotype 1b

genotype 2a

TPV (nM)

DAA

NS3 protease

PI

323.79

1.72

5.54

DPV (nM)

DAA

NS3 protease

PI

1.40

0.98

20.18

SMV (nM)

DAA

NS3 protease

PI

0.45

153.95

1.10

3.10

14.54

2.59

ASV (nM)

DAA

NS3 protease

PI

2.75

665.49

0.97

2.99

20.81

2.68

SOF (nM)

DAA

NS5B polymerase NI

NI

120.48

843.74

1.66

3.02

5.89

2.65

VX (pM)

DAA

NS5B polymerase NNI

NNI

107.58

1.81

5.08

DAS (nM)

DAA

NS5B polymerase NNI

NNI

1.50

7203.98

0.99

0.73

19.57

56.39

NSV (nM)

DAA

NS5B polymerase NNI

NNI

0.25

1.19

11.87

TGV (nM)

DAA

NS5B polymerase NNI

NNI

8.92

1.01

18.45

DCV (nM)

DAA

NS5A

NS5AI

0.10

0.13

1.11

3.68

14.19

2.23

LDV (nM)

DAA

NS5A

NS5AI

0.67

30.80

0.96

6.11

21.48

1.62

IFNα (IU/ml)

HTA

IFN

2.56

1.43

7.84

CsA (μg/m)

HTA

Cyclophilin

CI

0.40

1.53

6.85

SCY (μM)

HTA

Cyclophilin

CI

0.34

1.45

7.62